vs
Adaptive Biotechnologies Corp（ADPT）与牛津地产（IIPR）财务数据对比。点击上方公司名可切换其他公司
Adaptive Biotechnologies Corp的季度营收约是牛津地产的1.1倍（$71.7M vs $66.7M），牛津地产净利率更高（47.8% vs -18.9%，领先66.7%），Adaptive Biotechnologies Corp同比增速更快（51.0% vs -13.1%），过去两年Adaptive Biotechnologies Corp的营收复合增速更高（30.8% vs -6.0%）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
牛津地产是一家加拿大跨国企业，业务涵盖房地产投资、开发与物业管理。其投资组合包含写字楼、零售、工业、多户住宅、生命科学及酒店类资产。该公司1960年以私营企业形式创立，自2003年起成为安大略省市政雇员退休系统（OMERS）的全资子公司，总部设于多伦多，在纽约、伦敦、澳大利亚、新加坡及卢森堡均设有区域总部。
ADPT vs IIPR — 直观对比
营收规模更大
ADPT
是对方的1.1倍
$66.7M
营收增速更快
ADPT
高出64.2%
-13.1%
净利率更高
IIPR
高出66.7%
-18.9%
两年增速更快
ADPT
近两年复合增速
-6.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $66.7M |
| 净利润 | $-13.6M | $31.8M |
| 毛利率 | 74.6% | — |
| 营业利润率 | -17.8% | 47.8% |
| 净利率 | -18.9% | 47.8% |
| 营收同比 | 51.0% | -13.1% |
| 净利润同比 | 59.7% | -20.4% |
| 每股收益（稀释后） | $-0.08 | $1.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADPTIIPR
| Q4 25 | $71.7M | $66.7M | ||
| Q3 25 | $94.0M | $64.7M | ||
| Q2 25 | $58.9M | $62.9M | ||
| Q1 25 | $52.4M | $71.7M | ||
| Q4 24 | $47.5M | $76.7M | ||
| Q3 24 | $46.4M | $76.5M | ||
| Q2 24 | $43.2M | $79.8M | ||
| Q1 24 | $41.9M | $75.5M |
净利润ADPTIIPR
| Q4 25 | $-13.6M | $31.8M | ||
| Q3 25 | $9.5M | $29.3M | ||
| Q2 25 | $-25.6M | $26.0M | ||
| Q1 25 | $-29.9M | $31.1M | ||
| Q4 24 | $-33.7M | $40.0M | ||
| Q3 24 | $-32.1M | $40.2M | ||
| Q2 24 | $-46.2M | $42.0M | ||
| Q1 24 | $-47.5M | $39.4M |
毛利率ADPTIIPR
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
营业利润率ADPTIIPR
| Q4 25 | -17.8% | 47.8% | ||
| Q3 25 | 10.9% | 45.5% | ||
| Q2 25 | -42.5% | 45.9% | ||
| Q1 25 | -56.4% | 47.4% | ||
| Q4 24 | -71.3% | 54.7% | ||
| Q3 24 | -70.3% | 54.8% | ||
| Q2 24 | -109.6% | 53.1% | ||
| Q1 24 | -116.5% | 55.7% |
净利率ADPTIIPR
| Q4 25 | -18.9% | 47.8% | ||
| Q3 25 | 10.2% | 45.3% | ||
| Q2 25 | -43.5% | 41.4% | ||
| Q1 25 | -56.9% | 43.3% | ||
| Q4 24 | -71.0% | 52.2% | ||
| Q3 24 | -69.1% | 52.6% | ||
| Q2 24 | -107.0% | 52.6% | ||
| Q1 24 | -113.5% | 52.3% |
每股收益（稀释后）ADPTIIPR
| Q4 25 | $-0.08 | $1.07 | ||
| Q3 25 | $0.06 | $0.97 | ||
| Q2 25 | $-0.17 | $0.86 | ||
| Q1 25 | $-0.20 | $1.03 | ||
| Q4 24 | $-0.22 | $1.35 | ||
| Q3 24 | $-0.22 | $1.37 | ||
| Q2 24 | $-0.31 | $1.44 | ||
| Q1 24 | $-0.33 | $1.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | $47.6M |
| 总债务越低越好 | — | $393.7M |
| 股东权益账面价值 | $218.8M | $1.8B |
| 总资产 | $512.7M | $2.4B |
| 负债/权益比越低杠杆越低 | — | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资ADPTIIPR
| Q4 25 | $70.5M | $47.6M | ||
| Q3 25 | $55.0M | $41.9M | ||
| Q2 25 | $43.2M | $104.9M | ||
| Q1 25 | $50.6M | $133.3M | ||
| Q4 24 | $47.9M | $151.2M | ||
| Q3 24 | $38.1M | $172.4M | ||
| Q2 24 | $59.8M | $160.9M | ||
| Q1 24 | $71.2M | $173.5M |
总债务ADPTIIPR
| Q4 25 | — | $393.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADPTIIPR
| Q4 25 | $218.8M | $1.8B | ||
| Q3 25 | $204.4M | $1.9B | ||
| Q2 25 | $179.7M | $1.9B | ||
| Q1 25 | $190.4M | $1.9B | ||
| Q4 24 | $202.7M | $1.9B | ||
| Q3 24 | $223.8M | $1.9B | ||
| Q2 24 | $241.6M | $1.9B | ||
| Q1 24 | $274.9M | $2.0B |
总资产ADPTIIPR
| Q4 25 | $512.7M | $2.4B | ||
| Q3 25 | $490.6M | $2.3B | ||
| Q2 25 | $496.6M | $2.3B | ||
| Q1 25 | $510.9M | $2.4B | ||
| Q4 24 | $539.4M | $2.4B | ||
| Q3 24 | $558.5M | $2.4B | ||
| Q2 24 | $584.9M | $2.4B | ||
| Q1 24 | $620.3M | $2.4B |
负债/权益比ADPTIIPR
| Q4 25 | — | 0.21× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $198.2M |
| 自由现金流经营现金流 - 资本支出 | $1.4M | — |
| 自由现金流率自由现金流/营收 | 2.0% | — |
| 资本支出强度资本支出/营收 | 0.9% | — |
| 现金转化率经营现金流/净利润 | — | 6.22× |
| 过去12个月自由现金流最近4个季度 | $-48.9M | — |
8季度趋势，按日历期对齐
经营现金流ADPTIIPR
| Q4 25 | $2.1M | $198.2M | ||
| Q3 25 | $-7.1M | $45.6M | ||
| Q2 25 | $-12.4M | $48.4M | ||
| Q1 25 | $-28.5M | $54.2M | ||
| Q4 24 | $-12.5M | $258.4M | ||
| Q3 24 | $-27.1M | $64.9M | ||
| Q2 24 | $-17.3M | $64.2M | ||
| Q1 24 | $-38.4M | $71.6M |
自由现金流ADPTIIPR
| Q4 25 | $1.4M | — | ||
| Q3 25 | $-7.5M | — | ||
| Q2 25 | $-13.1M | — | ||
| Q1 25 | $-29.7M | — | ||
| Q4 24 | $-12.6M | — | ||
| Q3 24 | $-27.4M | — | ||
| Q2 24 | $-19.0M | — | ||
| Q1 24 | $-39.9M | — |
自由现金流率ADPTIIPR
| Q4 25 | 2.0% | — | ||
| Q3 25 | -8.0% | — | ||
| Q2 25 | -22.2% | — | ||
| Q1 25 | -56.7% | — | ||
| Q4 24 | -26.5% | — | ||
| Q3 24 | -59.0% | — | ||
| Q2 24 | -44.1% | — | ||
| Q1 24 | -95.2% | — |
资本支出强度ADPTIIPR
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 3.6% | — |
现金转化率ADPTIIPR
| Q4 25 | — | 6.22× | ||
| Q3 25 | -0.75× | 1.56× | ||
| Q2 25 | — | 1.86× | ||
| Q1 25 | — | 1.75× | ||
| Q4 24 | — | 6.46× | ||
| Q3 24 | — | 1.61× | ||
| Q2 24 | — | 1.53× | ||
| Q1 24 | — | 1.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
IIPR
暂无分部数据
